Catalyst Pharma Revenue, Profits - CPRX Quarterly Income Statement

Add to My Stocks
$3.07 $0.03 (0.97%) CPRX stock closing price Sep 19, 2018 (Closing)

Looking at financial statements, along with the Catalyst Pharma stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. Like any other income statement, the CPRX income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue decline of 0 when compared to the same period in the past. The operating expenses as shown in the Catalyst Pharma profit and loss statement for 2018 Q2 total to $6.33M. This line item shows that the operating expenses has increased compared with last year. Also check: Catalyst Pharma assets and Catalyst Pharma free cash flow.

View and download details of revenue and profits for Catalyst Pharma for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Catalyst Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
Catalyst Pharma Gross Profit
Research & Development Expense3.7M3.25M3.41M2.7M2.45M2.81M2.83M2.49M2.5M3.54M
Selling General & Admin Expense2.63M2.67M2.12M1.6M1.72M1.86M1.5M1.42M2.3M2.69M
Income Before Depreciation Depletion Amortization-6.34M-5.93M-5.52M-4.3M-4.18M-4.67M-4.33M-3.91M-4.81M-6.23M
Depreciation Depletion Amortization----------
Non Operating Income------0.28M--0.03M--
Interest Expense----------
Catalyst Pharma Pretax Income
Provision for Income Taxes----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-5.97M-5.7M-5.39M-4.18M-3.88M-4.97M-4.16M-3.95M-4.57M-5.39M
Extraordinary Items & Discontinued Operations----------
Catalyst Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS102.6M102.56M91.45M84.8M83.91M82.97M82.9M82.87M82.87M82.86M
Average Shares used to compute Basic EPS102.6M102.56M91.45M84.8M83.91M82.97M82.9M82.87M82.87M82.86M
Income Before Nonrecurring Items-5.97M-5.7M-5.39M-4.18M-4.09M-4.57M-4.27M-3.95M-4.72M-6.12M
Income from Nonrecurring Items------0.4M----
Catalyst Pharma Earnings Per Share Basic Net
Catalyst Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.06-0.06-0.06-0.05-0.05-0.06-0.05-0.05-0.06-0.07
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Catalyst Pharma stock analysis involves checking at least a few of the important things like:

  • Topline: A growing topline, as seen from the Catalyst Pharma revenue chart, as isn't the case with Catalyst Pharma indicates a sagging business. One needs to compare the QoQ topline or sales growth of CPRX stock with its peers like NUTR stock and ASRT stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-5.97M for Catalyst Pharma for 2018 Q2. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the CPRX income statement, one can check the Catalyst Pharma historical stock prices to check how the price has moved with time.

Catalyst Pharma Income Statement - Key Financial Ratios